Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with or without short-pulse laser for macular edema secondary to BRVO (Japan)
jRCT1080223399Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in branch retinal vein occlusion (BRVO) (2 arms), sponsored by Novartis. Primary endpoint: Number of ranibizumab retreatments from baseline to Month 12. Started Dec 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on jRCT1080223399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223399.